



CONTACT:  
Charles Robb  
Chief Financial Officer  
Corcept Therapeutics  
650-688-8783  
[crobb@corcept.com](mailto:crobb@corcept.com)  
[www.corcept.com](http://www.corcept.com)

**CORCEPT THERAPEUTICS TO ANNOUNCE THIRD QUARTER 2016  
FINANCIAL RESULTS AND CORPORATE UPDATE AND HOST CONFERENCE CALL**

**MENLO PARK, Calif.**, (October 26, 2016) – Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 1, 2016. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

**Conference Call Information**

To participate, dial 1-800-446-1671 from the United States or 1-847-413-3362 internationally approximately 10 minutes before the start of the call. The passcode is 43632675.

A replay will be available through November 15, 2016 at 1-888-843-7419 from the United States and 1-630-652-3042 internationally. The passcode is 43632675.

**About Corcept Therapeutics Incorporated**

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym<sup>®</sup> (mifepristone) 300 mg tablets, a first-generation cortisol modulator, is the company's first FDA-approved medication. The company also has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of serious disorders. It also holds composition of matter patents covering its selective cortisol modulators.